Center on Health Equity & Access

Nancy L. Lewis, MD, MBS, FACP, discusses her path from the clinic to biopharma and her goals as NCCN's new CSO, including health equity and faster drug development.

Two AAD 2026 posters highlight persistent melanoma disparities: men have worse survival, whereas minority patients are less likely to receive home or hospice end-of-life care.

Study finds rural Appalachia faces soaring insomnia and sleep apnea, tied to poverty and stress, urging targeted, equity-focused sleep interventions.

Major health plans cut millions of preapproval hurdles, add 90-day continuity protections, and push real-time e-authorization to speed care access.

Despite a 24% drop since 2015, over 4 million Americans remain on long-term opioids, and they’re older, on Medicare, and increasingly coprescribed risky drugs.

Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and formulary incentives.

Social determinants of health can delay access to NGS, limiting targeted therapy use and survival outcomes in advanced cancers.

ACIP changes threaten vaccine coverage and raise costs, according to a roundtable of experts warning of widening disparities and long-term public health risks.

Ajai Chari, MD, discusses the teclistamab-daratumumab approval, highlighting durable remissions, infection management, and the need for community oncologist uptake.

From teledermatology billing to rural outreach and transplant advances, new studies and presentations reveal shifts in access, equity, and patient outcomes.

Mammography use fell significantly among younger, uninsured, and non-Hispanic White and Asian women from 2002-2022, with the 2009 USPSTF guideline change a likely driver.

Continuing conversations from last year, experts at the AAD Annual Meeting in Denver weighed the pros and cons of teledermatology and AI.

Half of working-age Medicaid enrollees face disenrollment under national work requirements, despite having greater functional impairment than those who would comply.

Joseph Mikhael, MD, has spent decades advancing the treatment of multiple myeloma, and he’s been witness to a remarkable shift in outcomes among older adults.

A new approach to posttransplant prophylaxis for graft vs host disease promises to increase access to the procedure to patients from minority groups with blood cancers. Investigators are now studying a lower dose of the treatment to limit toxicity.

Experts at the 2026 AAD Annual Meeting urged dermatologists to engage in advocacy to protect practices and patient access amid growing challenges.

April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD.

Experts at the 2026 AAD Annual Meeting noted that, together, PCP support, community outreach, and teledermatology help reduce care gaps.

Clinicians need to adjust their diagnostic lens and counseling strategies in patients with skin of color, explained Joseph Lam, MD.

Experts at the 2026 AAD Annual Meeting explained that teledermatology helps dermatologists manage their workload and expand patient access beyond traditional in-person care.

Experts reflect on opioid policy impacts, IRA reforms and insulin caps impact drug access, and oncology leaders advance more equitable, integrated cancer care.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.

James Song, MD, discusses the direction teledermatology is heading and how more inclusive clinical trials can improve outcomes for patients of color.

A new analysis projects that millions will lose Medicaid expansion coverage—including many who are working, exempt, or have serious health needs.

A program in Detroit identified hundreds of patients with chronic kidney disease.